Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
Hims & Hers said it is beginning the rollout of its Peptides+ platform with five U.S.-compounded offerings: sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine. The company said none of these formulations is FDA-approved.
Why it matters — The rollout adds peptide and longevity treatments to Hims & Hers’ offerings, while their lack of FDA approval is relevant context for investors following the company.